This review highlights the clinical development program of rivaroxaban, an oral Factor Xa inhibitor approved for preventing and treating thrombosis-mediated conditions.
No takes yet. Share an insight, caveat, or question.
Multiple approvals enable rivaroxaban use across thrombotic conditions; extends the evidence base for oral Factor Xa inhibition.
Sarich et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: